Literature DB >> 6423814

Interactions between cyclophosphamide and adriamycin metabolism in rats.

P Dodion, C E Riggs, S R Akman, J M Tamburini, O M Colvin, N R Bachur.   

Abstract

Rat liver microsomes under anaerobic conditions metabolize adriamycin (ADM) to 7-deoxyadriamycinol aglycone and 7-deoxyadriamycin aglycone. The metabolism of ADM and the concentration of cytochrome P-450 were not affected by preincubation with 2.76 mM cyclophosphamide. After preincubation of microsomes with 0.2 mM 4-hydroperoxycyclophosphamide, a prodrug of 4-hydroxycyclophosphamide, there was complete denaturation of the cytochrome P-450, and 22.8% inhibition of NADPH-cytochrome P-450 reductase. Under these conditions, the degradation of ADM was delayed (area under the concentration vs. time curve in micromolar X minutes: 15.6 +/- 2.4 for the controls, and 59.8 +/- 7.3 in the presence of 4-hydroperoxycyclophosphamide, P less than or equal to .005), 7-deoxyadriamycin aglycone increased progressively to reach a plateau at 20 min instead of showing a peak at 2 min and the formation of 7-deoxyadriamycinol aglycone was reduced. Microsomes from animals pretreated with cyclophosphamide (180 mg/kg i.p. once 4 days before sacrifice) showed a 24.0% reduction of NADPH-cytochrome P-450 reductase activity (P less than or equal to .02). This was accompanied by a decreased formation of 7-deoxyadriamycinol aglycone during the first 20 min of incubation (area under the concentration vs. time curve in micromolar X minutes: 68.0 +/- 15.7 in the controls, and 25.6 +/- 3.1 in the treated animals, P less than or equal to .005), whereas the formation of 7-deoxyadriamycin animals, P less than or equal to .005), whereas the formation of 7-deoxyadriamycin aglycone was not affected. These data indicate an interaction between the metabolism of cyclophosphamide and ADM in rats.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423814

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

Authors:  W Linkesch; M Weger; I Eder; H W Auner; C Pernegg; C Kraule; M J Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

3.  The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits.

Authors:  D E Brenner; J C Collins; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Pharmacokinetic drug interactions with anticancer drugs.

Authors:  P M Loadman; M C Bibby
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

5.  Pharmacokinetics of doxorubicin in pregnant women.

Authors:  Rachel J Ryu; Sara Eyal; Henry G Kaplan; Arezoo Akbarzadeh; Karen Hays; Kristin Puhl; Thomas R Easterling; Stacey L Berg; Kathleen A Scorsone; Eric M Feldman; Jason G Umans; Menachem Miodovnik; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-15       Impact factor: 3.333

6.  Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.

Authors:  J Cummings; G J Forrest; D Cunningham; N L Gilchrist; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.